The Resonant Family

About Our Team

Our team of researchers, physicians, and business leaders is dedicated to transforming innovative research into impactful clinical solutions. Each member's expertise and commitment drive our mission to improve patient outcomes and advance healthcare.

At Resonant, we foster a culture of empathy, collaboration, and innovation, ensuring our efforts are always directed toward enhancing the lives of those we serve.

Chad Pollard

Co-Founder & CEO

As a PHD candidate in Genetics, Genomics, and Biotechnology, Chad pioneers pre-symptomatic NGS diagnostics.

Tim Jenkins, PHD

Co-Founder & VP of R&D

An Associate Professor of Cell Biology and Physiology at BYU, Tim is a pioneer in leveraging epigenetics as a clinically actionable diagnostic tool.

Adam Hewlett CPA


As CFO of Renew Biotechnologies, Adam leverages his deep expertise in accounting and finance—gained from significant startup roles, as well as roles at Ernst & Young and PricewaterhouseCoopers—to drive financial strategy and operational efficiency, consistently delivering exceptional financial stewardship and innovation in financial processes.

Jeffrey Burns, MD, MS

Research Advisor

As Co-Director of the University of Kansas Alzheimer’s Disease Research Center (KU ADRC), Dr. Burns's advisorship ensures Resonant's research is informed by clinical relevance and poised for translational success.

Ryan Miller, MS

Senior Data Scientist

From liquid biopsies to male fertility, Ryan has almost a decade of experience developing epigenetic-based assays.

Tanner Jensen

Director of Sales

With a rich foundation in Nursing and Healthcare Administration, his expertise uniquely enhances his role as a pivotal figure in the Biotech industry's sales landscape. As an accomplished sales leader, Tanner adeptly guides sales teams to remarkable success, consistently achieving multimillion-dollar results year after year.

Our Values

Resonant Values serve as the guiding principles to our organization's actions, culture, and relationships, creating a unified goal that amplifies productivity, morale, and overall success.


Integrity lies at the core of how we conduct our research, manage our business, and interact with each other and the communities we serve. This means upholding high ethical standards, being honest in our communications, and embracing responsibility in our decisions and their impacts.


Our commitment to innovation drives us to develop more effective solutions for patients with neurodegenerative diseases. We embrace leading technologies and novel research methodologies to create solutions with the potential to expedite diagnoses and significantly improve patient outcomes.


Empathy guides our approach to healthcare. We are dedicated to understanding and addressing the needs of patients, families, and caregivers affected by neurodegenerative diseases. This commitment not only influences our product development, but also the way we support each other within our team.


Our goal is to empower patients. We are developing tools to detect biomarkers of neurodegeneration earlier in disease progression. But these tools aren't just about detecting diseases earlier. They're about giving control back to the patients, empowering them to make informed decisions that enhance their quality of life.


We prioritize thorough validation of our tests to ensure that healthcare professionals and patients can make informed decisions based on dependable test results. Our rigorous approach supports better health outcomes, disease management, and treatment planning.